Recent concepts of antiangiogenic therapy

Konno, Hiroyuki; Yamamoto, Masayoshi; Ohta, Manabu

doi:10.1007/s00595-009-4150-2

Cited by 16Angiogenesis and VEGF in CancerColorectal Cancer Treatments and StudiesLymphatic System and Diseases

Recent concepts of antiangiogenic therapy

Konno, Hiroyuki, Yamamoto, Masayoshi, Ohta, Manabu·2010·Surgery Today

DOI 10.1007/s00595-009-4150-2

Open this paper in CoChat — free account

Abstract

In 2004, a randomized, controlled phase III clinical trial showed that the addition of bevacizumab, a humanized monoclonal antibody against vascular endothelial growth factor (VEGF)-A, to conventional chemotherapy prolonged the survival of patients with metastatic colorectal cancer. A number of clinical trials are presently underway to test the utility of several angiogenic inhibitors against a variety of malignancies. The original concept of antiangiogenic therapy was the inhibition of outgrowth of new blood vessels; however, it soon became evident that bevacizumab could affect the vasculature through various mechanisms. Recent studies have shown that antiangiogenic agents can normalize the tumor vasculature and prevent the recruitment of endothelial progenitor cells from the bone marrow. Some preclinical studies have also shown that antiangiogenic agents prevent metastasis by modulating the premetastatic niche. Understanding these detailed mechanisms provides the rationale for combination therapy using antiangiogenic agents and cytotoxic chemotherapy, and will lead to more effective treatment strategies. In this review, we summarize the present understanding of the mechanisms of action of antiangiogenic agents and discuss the future prospects of antiangiogenic therapies.

Integrity signals

Registry

Crossref · 10.1007/s00595-009-4150-2

Cites

45 of 45 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Addition of bevacizumab to standard first-line chemotherapy regimens significantly improved progression-free survival.
“In contrast, the addition of bevacizumab to standard first‐line chemotherapy regimens significantly improved progression‐free survival.”
From Hypoxia signaling in cancer: Implications for therapeutic interventions (2023) · cites this paper as [274]

Sorafenib in advanced hepatocellular carcinoma
Llovet, J. M., Ricci, S., Mazzaferro, V., Hilgard, P., Gane, E., Blanc, J.-F., de Oliveira, A. C., Santoro, A., Raoul, J.-L., Forner, A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0708857 · Cited by 13,097 · see citing works
Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032691 · Cited by 10,968 · see citing works
Tumor angiogenesis: therapeutic implications
Sherwood, L. M., Parris, E. E., & Folkman, J. (1971) · New England Journal of Medicine · doi:10.1056/nejm197111182852108 · Cited by 10,187 · see citing works
Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis
Hanahan, D., & Folkman, J. (1996) · Cell · doi:10.1016/s0092-8674(00)80108-7 · Cited by 6,885 · see citing works
Paclitaxel–Carboplatin Alone or with Bevacizumab for Non–Small-Cell Lung Cancer
Sandler, A., Gray, R., Perry, M. C., Brahmer, J., Schiller, J. H., Dowlati, A., Lilenbaum, R., & Johnson, D. H. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa061884 · Cited by 5,761 · see citing works
Sunitinib versus Interferon Alfa in Metastatic Renal-Cell Carcinoma
Motzer, R. J., Hutson, T. E., Tomczak, P., Michaelson, M. D., Bukowski, R. M., Rixe, O., Oudard, S. M., Négrier, S., Szczylik, C. A., Kim, S. T., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa065044 · Cited by 5,752 · see citing works
Sorafenib in Advanced Hepatocellular Carcinoma
정, 재. (2008) · Cited by 5,606 · see citing works
Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy
Jain, R. K. (2005) · Science · doi:10.1126/science.1104819 · Cited by 5,527 · see citing works
Sorafenib in Advanced Clear-Cell Renal-Cell Carcinoma
Escudier, B. J., Eisen, T. G., Stadler, W. M., Szczylik, C. A., Oudard, S. M., Siebels, M., Négrier, S., Chevreau, C., Solska, E., Desai, A. A., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa060655 · Cited by 4,802 · see citing works
VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche
Kaplan, R. N., Riba, R. D., Zacharoulis, S., Bramley, A. H., Vincent, L., Costa, C., MacDonald, D. D., Jin, D. K., Shido, K., Kerns, S. A., et al. (2005) · Nature · doi:10.1038/nature04186 · Cited by 3,288 · see citing works
Paclitaxel plus Bevacizumab versus Paclitaxel Alone for Metastatic Breast Cancer
Miller, K. D., Wang, M., Gralow, J. R., Dickler, M. N., Cobleigh, M., Perez, E. A., Shenkier, T. N., Cella, D. F., & Davidson, N. E. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa072113 · Cited by 3,077 · see citing works
Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial
Demetri, G. D., van Oosterom, A. T., Garrett, C. R., Blackstein, M. E., Shah, M. H., Verweij, J., McArthur, G. A., Judson, I. R., Heinrich, M. C., Morgan, J. A., et al. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69446-4 · Cited by 2,646 · see citing works
Transplacental Carcinogenesis by Stilbestrol
Folkman, J. (1971) · New England Journal of Medicine · doi:10.1056/nejm197108122850711 · Cited by 2,640 · see citing works
Normalizing tumor vasculature with anti-angiogenic therapy: A new paradigm for combination therapy
Jain, R. K. (2001) · Nature Medicine · doi:10.1038/nm0901-987 · Cited by 2,184 · see citing works
Impaired recruitment of bone-marrow–derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth
Lyden, D., Hattori, K., Dias, S., Costa, C., Blaikie, P., Butros, L., Chadburn, A., Heissig, B., Marks, W., Witte, L., et al. (2001) · Nature Medicine · doi:10.1038/nm1101-1194 · Cited by 1,860 · see citing works
VEGF-targeted therapy: mechanisms of anti-tumour activity
Ellis, L. M., & Hicklin, D. J. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2403 · Cited by 1,673 · see citing works
Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation
Winkler, F., Kozin, S. V., Tong, R. T., Chae, S.-S., Booth, M. F., Garkavtsev, I., Xu, L., Hicklin, D. J., Fukumura, D., di Tomaso, E., et al. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.10.011 · Cited by 1,170 · see citing works
Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity
Klement, G. L., Baruchel, S., Rak, J. W., Man, S., Clark, K., Hicklin, D. J., Böhlen, P., & Kerbel, R. S. (2000) · Journal of Clinical Investigation · doi:10.1172/jci8829 · Cited by 1,166 · see citing works
The vascular endothelial growth factor (VEGF)/VEGF receptor system and its role under physiological and pathological conditions
Takahashi, H., & Shibuya, M. (2005) · Clinical Science · doi:10.1042/cs20040370 · Cited by 950 · see citing works
Disrupting tumour blood vessels
Tozer, G. M., Kanthou, C., & Baguley, B. C. (2005) · Nature reviews. Cancer · doi:10.1038/nrc1628 · Cited by 931 · see citing works
Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiationRole of oxygenation, angiopoietin-1, and matrix metalloproteinases
WINKLER, F., Kozin, S. V., Tong, R. T., Chae, S.-K., Booth, M., Garkavtsev, I., Xu, L., Hicklin, D. J., Fukumura, D., & DiTomaso, E. (2004) · Cancer Cell · doi:10.1016/s1535-6108(04)00305-8 · Cited by 685 · see citing works
Endothelial Progenitor Cells Control the Angiogenic Switch in Mouse Lung Metastasis
Gao, D., Nolan, D. J., Mellick, A. S., Bambino, K., McDonnell, K., & Mittal, V. (2008) · Science · doi:10.1126/science.1150224 · Cited by 632 · see citing works
Effect of Vascular Normalization by Antiangiogenic Therapy on Interstitial Hypertension, Peritumor Edema, and Lymphatic Metastasis: Insights from a Mathematical Model
Jain, R. K., Tong, R. T., & Munn, L. L. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-4102 · Cited by 612 · see citing works
The multifaceted circulating endothelial cell in cancer: towards marker and target identification
Bertolini, F., Shaked, Y., Mancuso, P., & Kerbel, R. S. (2006) · Nature reviews. Cancer · doi:10.1038/nrc1971 · Cited by 575 · see citing works
Therapy-Induced Acute Recruitment of Circulating Endothelial Progenitor Cells to Tumors
Shaked, Y., Ciarrocchi, A., Franco, M., Lee, C. R., Man, S., Cheung, A., Hicklin, D. J., Chaplin, D. J., Foster, F. S., Benezra, R., et al. (2006) · Science · doi:10.1126/science.1127592 · Cited by 568 · see citing works
Phase II Clinical Trial of Bevacizumab and Low-Dose Metronomic Oral Cyclophosphamide in Recurrent Ovarian Cancer: A Trial of the California, Chicago, and Princess Margaret Hospital Phase II Consortia
García, A. A., Hirte, H. W., Fleming, G. F., Yang, D., Tsao-Wei, D. D., Roman, L. D., Groshen, S. G., Swenson, S. D., Markland, F. S., Gandara, D. R., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.1939 · Cited by 547 · see citing works
Genetic heterogeneity of the vasculogenic phenotype parallels angiogenesis
Shaked, Y., Bertolini, F., Man, S., Rogers, M. S., Cervi, D., Foutz, T. J., Rawn, K., Voskas, D., Dumont, D., Ben‐David, Y., et al. (2005) · Cancer Cell · doi:10.1016/j.ccr.2004.11.023 · Cited by 329 · see citing works
Vascular‐targeting therapies for treatment of malignant disease
Siemann, D. W., Chaplin, D. J., & Horsman, M. R. (2004) · Cancer · doi:10.1002/cncr.20299 · Cited by 314 · see citing works
Untitled work
(2001) · PubMed · Cited by 257 · see citing works
Circulating endothelial-cell kinetics and viability predict survival in breast cancer patients receiving metronomic chemotherapy
Mancuso, P., Colleoni, M. A., Calleri, A., Orlando, L., Maisonneuve, P., Pruneri, G., Agliano, A., Goldhirsch, A., Shaked, Y., Kerbel, R. S., et al. (2006) · Blood · doi:10.1182/blood-2005-11-4570 · Cited by 251 · see citing works
Circulating endothelial cells and angiogenic serum factors during neoadjuvant chemotherapy of primary breast cancer
Fürstenberger, G., von Moos, R., Lucas, R., Thurlimann, B. J. K., Senn, H.-J., Hamacher, J., & Boneberg, E.-M. (2006) · British Journal of Cancer · doi:10.1038/sj.bjc.6602952 · Cited by 205 · see citing works
Genetic heterogeneity of the vasculogenic phenotype parallels angiogenesisImplications for cellular surrogate marker analysis of antiangiogenesis
Shaked, Y., Bertolini, F., Man, S., ROGERS, M., Cervi, D. N., Foutz, T. J., Rawn, K., Voskas, D., Dumont, D. J., & Ben-David, Y. (2005) · Cancer Cell · doi:10.1016/s1535-6108(04)00369-1 · Cited by 202 · see citing works
Kinetics and viability of circulating endothelial cells as surrogate angiogenesis marker in an animal model of human lymphoma.
Monestiroli, S., Mancuso, P., Burlini, A., Pruneri, G., Dell’Agnola, C., Gobbi, A., Martinelli, G., & Bertolini, F. (2001) · PubMed · Cited by 159 · see citing works
Differential Effects of Vascular Endothelial Growth Factor Receptor-2 Inhibitor ZD6474 on Circulating Endothelial Progenitors and Mature Circulating Endothelial Cells: Implications for Use as a Surrogate Marker of Antiangiogenic Activity
Beaudry, P., Force, J. M., Naumov, G. N., Wang, A. Z., Baker, C. H., Ryan, A. J., Söker, S., Johnson, B. E., Folkman, J., & Heymach, J. V. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2271 · Cited by 158 · see citing works
Phase II Trial of Bevacizumab in Combination with Weekly Docetaxel in Metastatic Breast Cancer Patients
Ramaswamy, B., ELIAS, A. D., Kelbick, N., Dodley, A., Morrow, M., Hauger, M., Allen, J., Rhoades, C. A., Kendra, K. L., Chen, H. X., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2603 · Cited by 119 · see citing works
TSU68 Prevents Liver Metastasis of Colon Cancer Xenografts by Modulating the Premetastatic Niche
Yamamoto, M., Kikuchi, H., Ohta, M., Kawabata, T., Hiramatsu, Y., Kondo, K., Baba, M., Kamiya, K., Tanaka, T., Kitagawa, M., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-1748 · Cited by 105 · see citing works
Self-citation
Circulating Endothelial Cells as a Novel Marker of Angiogenesis
Mancuso, P., Calleri, A., Cassi, C., Gobbi, A., Capillo, M., Pruneri, G., Martinelli, G., & Bertolini, F. (2003) · Advances in experimental medicine and biology · doi:10.1007/978-1-4615-0169-5_9 · Cited by 89 · see citing works
Results of an interim analysis of a multinational randomized, double-blind, phase III study in patients (pts) with previously treated metastatic colorectal cancer (mCRC) receiving FOLFOX4 and PTK787/ZK 222584 (PTK/ZK) or placebo (CONFIRM 2)
Koehne, C., Bajetta, E., Lin, E. H., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.24.18_suppl.3508 · Cited by 87 · see citing works
Antitumor Effect of a Neutralizing Antibody to Vascular Endothelial Growth Factor on Liver Metastasis of Endocrine Neoplasm
Konno, H., Arai, T., Tanaka, T., et al. (1998) · Japanese Journal of Cancer Research · doi:10.1111/j.1349-7006.1998.tb00651.x · Cited by 48 · see citing works
Self-citation
Final results of CONFIRM 2: A multinational, randomized, double-blind, phase III study in 2nd line patients (pts) with metastatic colorectal cancer (mCRC) receiving FOLFOX4 and PTK787/ZK 222584 (PTK/ZK) or placebo
Köhne, C.-H., Bajetta, E., Lin, E. H., Valle, J. W., Cutsem, E. V., Hecht, J. R., Moore, M., Germond, C. J., Meinhardt, G., & Jacques, C. J. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.25.18_suppl.4033 · Cited by 47 · see citing works
Perioperative host-tumor inflammatory interactions: A potential trigger for disease recurrence following a curative resection for colorectal cancer
Miki, C., Tanaka, K., Inoue, Y., et al. (2008) · Surgery Today · doi:10.1007/s00595-007-3674-6 · Cited by 34 · see citing works
Biallelic mutations of the Tsc2 gene in chemically induced rat renal cell carcinoma
Satake, N., Urakami, S., Hirayama, Y., Izumi, K., & Hino, O. (1998) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19980911)77:6 · Cited by 30 · see citing works
TSU68, an antiangiogenic receptor tyrosine kinase inhibitor, induces tumor vascular normalization in a human cancer xenograft nude mouse model
Ohta, M., Kawabata, T., Yamamoto, M., et al. (2009) · Surgery Today · doi:10.1007/s00595-009-4020-y · Cited by 28 · see citing works
Self-citation
Interstitial fluid pressure (IFP) predicts disease-free survival independent of clinical prognostic factors in cervix cancer patients treated with radiotherapy
Milosevic, M., Fyles, A., Pintilie, M., et al. (2000) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/s0360-3016(00)80065-6 · Cited by 6 · see citing works
Combination treatment improves breast-cancer survival
Senior, K. (2006) · The Lancet Oncology · doi:10.1016/s1470-2045(06)70682-9 · Cited by 3 · see citing works

Flagged first, then by citations

Sorted by citations

Hypoxia signaling in cancer: Implications for therapeutic interventions
Zhuang, Y., Liu, K., He, Q., Gu, X., Jiang, C., & Wu, J. (2023) · MedComm · doi:10.1002/mco2.203 · Cited by 119 · see citing works

Intracranial hemorrhage in patients treated with bevacizumab：Report of two cases
Takeshi, Nishimura, Makoto, M., et al. (2011) · Acta Scientiarum Naturalium Universitatis Sunyatseni
Bevacizumab 5 or 7.5 mg/kg in Metastatic Colorectal Cancer Can Be Infused Safely Over 10 Minutes
Mahfoud, T., Tanz, R., Mesmoudi, M., et al. (2011) · Journal of Gastrointestinal Cancer · doi:10.1007/s12029-010-9245-x · Cited by 5 · see citing works
Bevacizumab Can Be Infused Safely Over 10 Minutes in Metastatic Colorectal Cancer
Mahfoud, T., & Réda, K. M. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu165.178
Two Cases of Leg Ulcer Caused by Bevacizumab
Jinnai, S., SUENAGA, A., Murata, M., et al. (2017) · The Nishinihon Journal of Dermatology · doi:10.2336/nishinihonhifu.79.468 · Cited by 1 · see citing works
Two Cases of Emergency Operations in Patients Undergoing Bevacizumab Treatment
Yoshikawa, K., Shimada, M., Kurita, N., et al. (2010) · Nihon Daicho Komonbyo Gakkai Zasshi · doi:10.3862/jcoloproctology.63.56 · Cited by 3 · see citing works

Authors: Konno, H., Yamamoto, M., & Ohta, M.
Affiliations: Hamamatsu University (JP)
ORCID: Konno, Hiroyuki
Yamamoto, Masayoshi
Venue: Surgery Today
Publisher: Springer Science and Business Media LLC
Published: 2010-05-23
Volume: 40
Issue: 6
Pages: 494-500
ISSN: 0047-1909 (ISSN-L)
0941-1291
1436-2813
DOI: 10.1007/s00595-009-4150-2
OpenAlex: W2021052565
Cited by: 16
References: 45
Citations by year: 2024: 1 · 2023: 1 · 2019: 1 · 2018: 1 · 2017: 2 · 2013: 2 · 2012: 2
FWCI: 0.28
Type: journal article
Language: en
Open access: closed
Licence: www.springer.com/tdm (tdm)
Locations: Surgery Today (publishedVersion)
PubMed (publishedVersion)
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
Health Sciences › Medicine › Oncology › Lymphatic System and Diseases
Keywords: anti-angiogenic therapy, bevacizumab, VEGF-A, metastatic colorectal cancer, tumor vasculature normalization, endothelial progenitor cells, pre-metastatic niche, metastasis prevention, combination chemotherapy, angiogenesis inhibitors, mechanism of action
MeSH terms: Bevacizumab, Antibodies, Monoclonal, Humans, Neovascularization, Pathologic, Colorectal Neoplasms, Angiogenesis Inhibitors, Antibodies, Monoclonal, Humanized

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Recent concepts of antiangiogenic therapy

Abstract

Integrity signals

Claims the paper makes

Claims other papers make about this one

Cites

Cited by

Related

Record

About these checks